Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:09 AM
Ignite Modification Date:
2025-12-25 @ 4:09 AM
NCT ID:
NCT02098720
Eligibility Criteria:
Inclusion Criteria:
1. Patients give fully informed consent and are willing and able to comply with all study procedures.
2. In the study eye:
There are primary or recurrent subfoveal or parafoveal active choroidal neovascularization (CNV) lesions secondary to wAMD.
The criterion of active CNV should meet at least one of following three conditions :
* fresh bleeding;
* neurosensory detachment showed on optical coherence tomography(OCT);
* leakage showed on fundus fluorescein angiography (FFA).
3. BCVA in study eye \< 19 letters (approximately 20/400 Snellen equivalent).
Exclusion Criteria:
1. Past or existing non-exudative AMD in study eye decided by investigator that have affected macular detection or central vision;
2. Subretinal hemorrhage in study eye and bleeding area ≥6 disc areas;
3. History of vitreous hemorrhage within last month;
4. The maximum diameter of scar and fibrosis area ≥500μm at subfoveal in study eye;
5. Photodynamic therapy (PDT) or drug treatment of CNV within last 6 months in study eye, or anti-vascular endothelial growth factor (VEGF) therapy in fellow eye within last month;
6. History of glaucoma in study eye;
7. Aphakia (excluding artificial lens) in the study eye.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT02098720
Study Brief:
Protocol Section:
NCT02098720